
Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
The results of a large, retrospective study of patients who received a form of immunotherapy…
Bristol Myers Squibb (NYSE: BMY) announced that the European Commission (EC) has approved Opdivo (nivolumab)…
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers…
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted…
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who…
A pioneering lung cancer study, led by the University of Birmingham’s Cancer Research UK Clinical…
Size and number of fused cancer and immune cells linked to survival in non-small cell…
The Oncology Podcast, brought to you by www.oncologynews.com.au, is proud to present the next episode…
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping…